Cedar Brook Financial Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-11,250
| Closed | -$610K | – | 60 |
|
|
2024
Q1 | $610K | Buy |
11,250
+333
| +3% | +$18.1K | 0.12% | 178 |
|
|
2023
Q4 | $548K | Buy |
10,917
+869
| +9% | +$43.6K | 0.12% | 182 |
|
|
2023
Q3 | $583K | Sell |
10,048
-253
| -2% | -$14.7K | 0.15% | 148 |
|
|
2023
Q2 | $659K | Buy |
10,301
+1,930
| +23% | +$123K | 0.16% | 146 |
|
|
2023
Q1 | $580K | Buy |
8,371
+1,451
| +21% | +$101K | 0.15% | 157 |
|
|
2022
Q4 | $498K | Buy |
6,920
+1,110
| +19% | +$79.9K | 0.14% | 172 |
|
|
2022
Q3 | $413K | Buy |
5,810
+2,306
| +66% | +$164K | 0.13% | 187 |
|
|
2022
Q2 | $270K | Buy |
3,504
+483
| +16% | +$37.2K | 0.08% | 261 |
|
|
2022
Q1 | $221K | Buy |
+3,021
| New | +$221K | 0.06% | 341 |
|
|
2021
Q3 | – | Sell |
-3,072
| Closed | -$205K | – | 353 |
|
|
2021
Q2 | $205K | Sell |
3,072
-126
| -4% | -$8.41K | 0.06% | 351 |
|
|
2021
Q1 | $202K | Sell |
3,198
-926
| -22% | -$58.5K | 0.07% | 304 |
|
|
2020
Q4 | $256K | Sell |
4,124
-929
| -18% | -$57.7K | 0.09% | 247 |
|
|
2020
Q3 | $305K | Buy |
5,053
+166
| +3% | +$10K | 0.12% | 198 |
|
|
2020
Q2 | $287K | Buy |
4,887
+799
| +20% | +$46.9K | 0.13% | 196 |
|
|
2020
Q1 | $228K | Sell |
4,088
-543
| -12% | -$30.3K | 0.13% | 205 |
|
|
2019
Q4 | $297K | Buy |
+4,631
| New | +$297K | 0.13% | 207 |
|